"I'm inclined to think this paves the way for a smooth...

"I'm inclined to think this paves the way for a smooth transition should Teva elect not to proceed with the trial beyond the interim analysis stage"

Is this your view Madam ? Of course it is ..your so lightning quick at "analysis" ...you leave other commentators for dust.

The reason provided by our CEO is as follows:
"Targeting patients at high risk of HF-MACE and advanced heart failure could facilitate the shortest Phase 3 program, the fastest time to market, and the opportunity for the most attractive pricing".

Making a difference to the very high sick patients - is not a good reason ? (AND if that gets us to market earlier that would be a huge bonus to all Stakeholders ).

BUT your analysis/reason is of course "transitioning for Teva in case they pull out".

Something doesn't feel right here again ?

GLTAH